Skip to content

LSD: all studies

Page 95 of 282: studies 941 to 950 of 2,815, newest first. Back to the LSD overview

Research

Model Psychoses Induced by LSD-25 in Normals

A M A Archives of Neurology & Psychiatry June 1, 1956 Nicholas A. Bercel 35 citations

INTRODUCTION Experimental psychosis has a long history. It might have started with the administration of Cannabis indica boiling in wine to the ancient Hun warriors, resulting in mental obfuscation, as they were prepared for surgery because of wounds sustained in battle. Scientific experimental psychiatry began toward the end of the last century, in the Kraepelinian era—when the organic theory...

DOI: 10.1001/archneurpsyc.1956.02330240026003 (opens in new tab) Mescaline Cannabis Methaqualone Schizophrenia object-oriented programming +6

Effects of Mescaline, LSD-25, and Adrenochrome on Depth Electrograms in Man

Archives of Neurology And Psychiatry June 1, 1956 Bert E. Schwarz 49 citations

In a recent report concerning the reversibility by chlorpromazine of psychoses induced by means of mescaline andd-lysergic acid diethylamide (LSD-25), careful attention was given to the clinical and electroencephalographic changes.1Although the clinical changes of this reversal effect were immediate and striking, the conventional electroencephalographic changes were minimal, and it was...

Some Effects of Bufotenine and Lysergic Acid Diethylamide on the Monkey

Archives of Neurology And Psychiatry 1956 Edward V. Evarts 52 citations

INTRODUCTION Bufotenine (5 -hydroxy -3 -[2- dimethyl-aminoethyl]-indole) is the N-dimethyl derivative of the vasoconstrictor substance serotonin (5-hydroxytryptamine). It was first synthesized by Wieland in 1934. Raymond-Hamet found that intravenous injection of bufotenine caused transient elevation of blood pressure and apnea, followed by tachypnea, in anesthetized dogs.* To date, however,...

Comparative subjective effects of seven drugs including lysergic acid diethylamide (LSD-25).

Journal of Abnormal & Social Psychology November 1, 1955 Murray E. Jarvik, Harold A. Abramson, Martin Hirsch 32 citations

Five Ss were tested on nine occasions under two placebos of tap water and under an average effective dose of 7 drugs--ergometerine (Ergonovine), ethyl alcohol, scopolamine (hyroscine), d-1-brom lysergic acid diethylamide (BOL-148), methamphetamine hydrochloride (Methedrine or Pervitin), lysergic acid monoethylamide (LAE-32), and lysergic acid diethylamide (LSD-25) during 9 different...

Lysergic Acid Diethylamide (Lsd-25): Ix. Effect on Snails

The Journal of Psychology October 1, 1955 Harold A. Abramson, Murray E. Jarvik 10 citations

"Certain species of snails are at least as sensitive to lysergic acid diethylamide (LSD-25) as are the Siamese fighting fish (Betta splendens). Ambularia cuprina (Mystery Snail) responds to LSD-25 with a typical, persistent, disorganized movement of the gastropod. This movement persists many hours and markedly alters the behavior of the snail. D-1-bromlysergic acid diethylamide (BOL-148) does...

Lysergic Acid Diethylamide (Lsd-25): Xvi. the Effect on Intellectual Functioning as Measured By the Wechsler-Bellevue Intelligence Scale

The Journal of Psychology October 1, 1955 Adam I. Levine, Harold A. Abramson, S. Markham 21 citations

(1955). Lysergic Acid Diethylamide (Lsd-25): Xvi. the Effect on Intellectual Functioning as Measured By the Wechsler-Bellevue Intelligence Scale. The Journal of Psychology: Vol. 40, No. 2, pp. 385-395.

Frenquel, a Blocking Agent Against Experimental LSD‐25 and Mescaline Psychosis

Neurology May 1, 1955 Howard D. Fabing 41 citations

Background: Patients with ALS commonly exhibit pseudobulbar affect. Methods: The authors conducted a multicenter, randomized, double-blind, controlled, parallel, three-arm study to test a defined combination of dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) (AVP-923) for the treatment of pseudobulbar affect in ALS. Q inhibits the rapid first-pass metabolism of DM. The effects of...

DOI: 10.1212/wnl.5.5.319 (opens in new tab) Discontinuation Dextromethorphan Randomized controlled trial Adverse effect +2